SEC Filing Summary: Seneca Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Seneca Biopharma, Inc. (not Palisade Bio, Inc.) on May 21, 2020. The registrant is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol SNCA. The filing serves as a Regulation FD Disclosure regarding the company's outstanding share count as of the report date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific corporate event rather than a comprehensive financial statement.
Material Changes
The primary disclosure in this filing is the confirmation of the company's capital structure as of May 21, 2020:
- Common Stock Outstanding: 12,299,307 shares (par value $0.01 per share).
No other material changes to financial position or operations are detailed in this specific text.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard legal disclaimer that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Seneca Biopharma, Inc. (SNCA), not Palisade Bio, Inc.
- Confirm the outstanding share count of 12,299,307 shares against subsequent filings or stock exchange data.
- Review the company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K does not contain them.